业界动态监管公开信息 · FDA
FDA批准vorasidenib用于携带易感IDH1或IDH2突变的2级星形细胞瘤或少突胶质细胞瘤
FDA Drugs · 2026-11-10 05:50
摘要
2024年8月6日，美国食品药品监督管理局批准vorasidenib（Voranigo，Servier Pharmaceuticals LLC），一种异柠檬酸脱氢酶-1（IDH1）和异柠檬酸脱氢酶-2（IDH2）抑制剂，用于12岁及以上的成人和儿童患者。了解更多。
English
FDA approves vorasidenib for Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation
On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, for adult and pediatric patients 12 years and older. Learn more.